News

Jan 21, 2026

New Partnership with KYE Pharmaceuticals

We’re pleased to share that Neurim Pharmaceuticals has signed an exclusive licensing and distribution agreement with KYE Pharmaceuticals Inc. to bring Slenyto to the Canadian market.

This partnership marks a significant milestone in our global expansion, offering a safe and effective solution that improves both sleep and daytime functioning in children with Autism Spectrum Disorder (ASD) and Smith-Magenis Syndrome (SMS) worldwide.
Read the full press release here: https://lnkd.in/eej-6wyf